2018 - Page 620 of 889 - Bay Street News

NASDAQ Companies - November 11, 2018

Clinically Meaningful Outcome in NIH Trial of MPC-150-IM for Heart Failure LVAD Recipients Provides Pathway for Potential Regulatory Approval

NEW YORK and MELBOURNE, Australia, Nov. 11, 2018 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that results from […]

NASDAQ Companies - November 11, 2018

Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500

NK100 Shows Clinical Benefit in Treating Advanced Hematologic Malignancies and Solid Tumors Disease Control Shown in All Subjects Re-treated with […]

NYSE Companies - November 11, 2018

Marine Harvest ASA – Mandatory notification of trade

Framar AS (Framar), a company controlled by Marine Harvest ASA’s (Marine Harvest) Chairman Ole-Eirik Lerøy, and Sterna Finance Ltd (Sterna), […]

NASDAQ Companies - November 11, 2018

GW4, the Met Office, and Cray Power Up the Largest Arm-Based Supercomputer in Europe

“Isambard” Supercomputer to Be Used for Scientific Research and Building the Next Generation of Computing Technology in the Exascale Era […]

NYSE Companies - November 11, 2018

New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients

Entresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in […]

NASDAQ Companies - November 10, 2018

Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting

CPI-444 demonstrated prolonged survival in patients with refractory renal cell carcinoma both as a monotherapy and in combination with atezolizumab […]

NASDAQ Companies - November 10, 2018

Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite Endpoint

Landmark Cardiovascular Risk Reduction Benefits Demonstrated in REDUCE-IT Are Largest of Any Major Cardiovascular Outcomes Study of a Drug Intended […]